Log In
BCIQ
Print this Print this
 

MU1140-S

  Manage Alerts
Collapse Summary General Information
Company Oragenics Inc.
DescriptionSynthetic version of lantibiotic MU1140 produced using differentially protected orthogonal lantionine technology (DPOLT)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationGram-positive bacterial infection
Indication DetailsTreat Gram-positive bacterial infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today